We are excited to announce that Eagle IP has been named as a finalist for the Life Sciences Patent Network (LSPN) Awards USA 2025 in the following categories:   

  1. Inspiring Woman of the Year: This nomination recognizes our President and Managing Director, Ms. Jennifer Che, for her outstanding leadership, innovation, and dedication to empowering others in the industry.  
  1. International Firm of the Year: This nomination recognizes the excellence and achievements of international firms, such as Eagle IP. 

We are truly honored to be shortlisted in two different categories for the LSPN Awards USA 2025!  This award recognizes "excellence, innovation, and leadership in life sciences IP" and tries to identify individuals and organizations that are "shaping the future of pharmaceutical and biotech patent protection." This recognition is a testament to the hard work and dedication of our entire team. A heartfelt THANK YOU to our clients for your trust and support, to our incredible team for their continued pursuit of excellence, and to our partners for their collaboration. 

You can see all the finalists here. 

我们的过去活动

Dr. Jacqueline Lui, Ms. Pauli Wong, and Mr. Eddie Ho Named Patent Stars by ManagingIP

2025年6月13日

Eagle IP Ranked Among Top Tier Firms in IAM Patent 1000

2025年6月12日

Jennifer Che from Eagle IP to Attend BIO 2025 in Boston!

2025年6月11日

Insights from HKSTP Market Discovery - BIO Connect

2025年5月28日

HKMHDIA Medical Fair Forum

2025年5月27日

Celebrating Innovation at the Asia Summit for Global Health

2025年5月26日

Recommended Insights

Can Post Filing Data Overcome Inventive Step in China?

2018年11月19日
Since 2010, the Patent Re-examination Board (PRB) has published the top 10 patent invalidation cases of the year in April of each year. The selection criteria are high social concern, significant impact on the related industry, or involve difficult legal issues and important examination criteria. Below is one of the top 10 cases that discusses […]
阅读更多 >

How to Protect a Crystal Form (Polymorph) Patent in China

2025年6月4日
Crystalline forms are critical to pharmaceutical patents, offering extended protection for improved stability, bioavailability, or manufacturability. However, securing such patents in China has grown increasingly difficult due to the China National Intellectual Property Administration (CNIPA)’s strict patentability criteria. Unlike the U.S. or Europe, where structural novelty or problem-solving utility may suffice, China demands quantifiable evidence of […]
阅读更多 >

Amendments to the China Patent Examination Guidelines in 2022 - Part 1: New rules for designs in view of China signing onto the Hague Agreement

2022年12月2日
This year, China stepped further onto the international scene by signing on as a member of the Hague Agreement. The Hague Agreement is an international registration system allowing applicants to file a single international design application in a single language to obtain protection in over 100 designated member countries. The US has been a member […]
阅读更多 >

What is the difference between an Invention Patent and a Utility Model Patent?

2021年8月13日
There are two types of patent protection in China. Invention patents (similar to a US utility patent) have a term of 20 years from the date of filing and may be granted for both methods and products. Utility model patents (similar to a petty patent) may be granted in China for technical solutions that relate […]
阅读更多 >
Top crossarrow-right